IPO Timeline
Broker Results (T-2)
2022-03-29
Some brokers release in afternoon
Grey Market (T-1)
2022-03-30
Afternoon
HKEX Allotment (T-1)
2022-03-30
Evening
Registrar Allotment (T-1)
2022-03-30
Evening
Listing Day (T)
2022-03-31
First day of trading
Company Overview
| Stock Name | 江蘇瑞科生物技術股份有限公司 - B - H股 |
|---|---|
| Stock Code | 02179 |
| Company Full Name | 江蘇瑞科生物技術股份有限公司 - B - H股 |
| Industry | 醫療保健 |
| Principal Activities | 主要於中國從事疫苗研發業務。 |
| Listing Date | 2022-03-31 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省泰州市中國醫藥城疫苗工程中心A217室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.recbio.cn |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 24.80 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 54.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 76,520,400 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 25.25 |
|---|---|
| First Day Open | HK$ 25.0 |
| First Day Change | 1.81% |
| First Day Volume | 3440000.0 |
| First Day Turnover | 86207200.0 |
Use of Proceeds
| Use of Proceeds | 1、約47.3%或317.9百萬港元將分配予繼續優化、開發及商業化我們的HPV疫苗管線； 2、約17.7%或119.3百萬港元將用于我們新冠肺炎疫苗（即ReCOV）的臨床前及臨床研究、注冊； 3、約21.1%或142.0百萬港元將用于其他候選疫苗的臨床前及臨床研究、注冊； 4、約6.7%或44.7百萬港元將用于進一步加強我們的研發能力及提高營運效率；5、約7.2%或48.5百萬港元將用作我們的營運資金及一般企業用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (3)
摩根士丹利亚洲有限公司 CE AAD291
招银国际融资有限公司 CE AVM940
中信证券（香港）有限公司 CE AAK249
Overall Coordinators (3)
摩根士丹利亚洲有限公司 CE AAD291
招银国际融资有限公司 CE AVM940
中信里昂证券有限公司 CE AAB893
Joint Bookrunners (8)
摩根士丹利亚洲有限公司 CE AAD291
招银国际融资有限公司 CE AVM940
中信里昂证券有限公司 CE AAB893
兴证国际融资有限公司 CE BAK956
海通国际证券有限公司 CE AAF806
GF Securities (Hong Kong) Brokerage Limited CE AOB364
安信国际证券(香港)有限公司
华盛资本证券有限公司 CE AUL711
Joint Lead Managers (9)
摩根士丹利亚洲有限公司 CE AAD291
招银国际融资有限公司 CE AVM940
中信里昂证券有限公司 CE AAB893
兴证国际融资有限公司 CE BAK956
海通国际证券有限公司 CE AAF806
GF Securities (Hong Kong) Brokerage Limited CE AOB364
安信国际证券(香港)有限公司
华盛资本证券有限公司 CE AUL711
利弗莫尔证券有限公司 CE BJN764
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Harvest International Premium Value (Secondary Market) Fund SPC | 78,231,600 HKD | — | 10.22% | — | 6 months | 2022-09-30 |
| 2 | SCC Growth VI Holdco C (HK) Limited | 7,812,000 HKD | — | 1.02% | — | 6 months | 2022-09-30 |
| 3 | SCHP Master Fund | 15,636,400 HKD | — | 2.04% | — | 6 months | 2022-09-30 |
| 4 | 扬子江(香港)有限公司 | 312,938,800 HKD | — | 40.90% | — | 6 months | 2022-09-30 |
Directors & Management
| Chairman | 徐浩宇 |
|---|---|
| Company Secretary | 魏其芳,孫嘉恩 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 泰州元工科技合伙企業(有限合伙)(17.16%);君聯資本管理股份有限公司(8.67%);上海超瑞醫藥科技合伙企業(有限合伙)(7.74%);深圳市東方富海投資管理股份有限公司(6.89%);深圳前海沃盈投資管理有限公司(5.63%) |
|---|
IPO Timeline
